喹硫平治疗躯体形式障碍临床研究  

Quetiapine in the Treatment of Somatoform Disorder

作　　者：张传海[1] 贺朝晖[1] 孙玉军[1] 王鹏举[1] 徐建龙[1] 吴鹏飞[1] 

机构地区：[1]中国江苏省昆山市第三人民医院,215311

出　　处：《中国健康心理学杂志》2013年第11期1629-1631,共3页China Journal of Health Psychology

基　　金：2011年昆山市科技局指令性项目(编号:ks153)

摘　　要：目的 观察喹硫平单药治疗躯体形式障碍的临床疗效、副反应.方法 选取我院门诊符合CCMD-3躯体形式障碍诊断标准患者按来院次序分为A（喹硫平单药）、B（文拉法辛单药）、C（喹硫平与文拉法辛合用）3组,每组各30例.分别给予喹硫平单药25～200mg/d、文拉法辛单药75～ 225 mg/d、喹硫平25～200mg/d与文拉法辛75～225mg/d合用治疗.治疗前与治疗第4、8周后评定症状自评量表（SCL-90）,副反应量表（TESS）.结果 3组SCL-90总分及各因子分评分在治疗4、8周后与治疗前比较差异有统计学意义（P＜0.01）.在4、8周后躯体化及总分方面,3组组间两两比较差异有统计学意义（P＜0.01）,合并用药组优于文拉法辛组,文拉法辛组优于喹硫平组.TESS无统计学意义.结论 喹硫平单药治疗躯体形式障碍疗效肯定,但疗效弱于文拉法辛单药,喹硫平与文拉法辛合用疗效最好,副反应相当.Objective To observe the clinical efficacy and side effects of quetiapine monotherapy in the treatment of somatoform disorders. Methods Patients in accordance with CCMD -3 with somatoform disorder diagnosis standard in our hospital outpatient service were divided into A （quetiapine）, B （venlafaxine）, C （quetiapine and venlafaxine）3 groups according to the visiting order, each group 30 cases, quetiapine 25 to 200 mg,venlafaxine 75 - 225 mg,25 ~ 200 mg of quetiapine and venlafaxine 75 - 225 mg of the treatment. Before and 4,8 weeks after treatment, SCL - 90 and TESS were used to assess . Results There were significant differences in SCL - 90 total score and factor scores of three groups between before treatment and in 4 weeks and 8 weeks after treatment（P 〈 0.01 ）. In 4 weeks and 8 weeks after treatment, there were significant differences in SCL -90 total score and somatization among three groups （P 〈 O. 01 ） ,the drug combination group was better than the venlafaxine group, the venlafaxine group was better than the quetiapine group. There was no statistical significance in TESS （P 〉 0. 05）. Conclusion Quetiapine monotherapy has certain curative effect in the treatment of somatoform disorders, but it is worse than venlafaxine, quetiapine with venlafaxine,their side effects are the same.

关 键 词：精神卫生 躯体形式障碍 随机对照试验 喹硫平 文拉法辛 

分 类 号：R749[医药卫生—神经病学与精神病学]